Monograph

J05AH01 - Zanamivir

Not porphyrinogenic

Rationale

Insignificant systemic exposure. The substance is not metabolised and does not interact with CYPs.

Chemical description

Antiviral neuramidase inhibitor used (inhalation 2x5 mg twice daily for 5 days) in symptomatic influenza A and B in adults and children > 12 years. The dose is deposited (about 80%) in oropharynx. Eliminated from there to the gastrointestinal tract with bioavailability of only 2 %. No metabolism takes place. No interaction with the metabolism of other drugs is observed.

Similar drugs

Explore alternative drugs in similar therapeutic classes J05A / J05AH or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames